[Novel anti-CML agents beyond imatinib].
Kimura
Shinya
S
D000255:Adenosine Triphosphate / Q000378:metabolism; D000814:Aniline Compounds; D000970:Antineoplastic Agents / Q000145:classification / Q000378:metabolism; D001549:Benzamides; D001555:Benzene Derivatives; D001665:Binding Sites; D001667:Binding, Competitive; D000069439:Dasatinib; D015195:Drug Design; D016044:Fusion Proteins, bcr-abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000209:etiology; D009570:Nitriles; D010879:Piperazines / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000145:classification / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D011743:Pyrimidines / Q000378:metabolism; D011804:Quinolines; D013844:Thiazoles; D003521:Cyclopropanes; D011720:Pyrazoles
D000255:Adenosine Triphosphate; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D001549:Benzamides; D001555:Benzene Derivatives; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl; D000068877:Imatinib Mesylate; D009570:Nitriles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D011743:Pyrimidines; D011804:Quinolines; D013844:Thiazoles; C499758:ON012380; C484810:tozasertib; D003521:Cyclopropanes; D011720:Pyrazoles; C471992:bosutinib; C498826:nilotinib; C506918:bafetinib